NASDAQ:ATOS

Atossa Genetics Stock Insider Trading

etoro logo Buy ATOS
*Your capital is at risk
$1.83
-0.180 (-8.96%)
At Close: Jun 22, 2026

Atossa Genetics Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 100.00. In total, the insiders bought 27.46M and sold 100K ATOS shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power

(Last 100 transactions)
100.00
Buy 27.46M shares
Sell 100K shares
98% Buy Activity
Negligible or No Correlation

No Significant Signals

No statistically significant buy or sell signals detected in recent insider data.

Historical Insider Trades

Date Type Person Role Amount
May 12, 2026
Buy
Common Stock
A-Award
Cigler Tessa
Director
Director 10 000
Value: $51.6K
May 12, 2026
Buy
Common Stock
A-Award
Galli Stephen J
Director
Director 10 000
Value: $51.6K
May 12, 2026
Buy
Common Stock
A-Award
Finn Jonathan
Director
Director 10 000
Value: $51.6K
May 12, 2026
Buy
Common Stock
A-Award
Remmel H. Lawrence
Director
Director 10 000
Value: $51.6K
May 12, 2026
Buy
Common Stock
A-Award
Chen Shu-chih
Director
Director 10 000
Value: $51.6K
May 12, 2026
Buy
Common Stock
A-Award
Steinhart Richard I
Director
Director 10 000
Value: $51.6K
Mar 27, 2026
Buy
Common Stock
A-Award
Quay Steven C
President & CEO
CEO / President 65 000
Value: $306.8K
Mar 26, 2026
Buy
Common Stock
A-Award
Daniel Mark James
Chief Financial Officer
C-Suite Officer 63 000
Value: $296.7K
Jan 20, 2026
Buy
Common Stock
A-Award
Quay Steven C
President & CEO
CEO / President 331 674
Value: $3.00M
Jan 20, 2026
Buy
Common Stock
A-Award
Quay Steven C
President & CEO
CEO / President 325 203
Value: $2.94M
Jan 20, 2026
Buy
Stock Options (right to buy)
A-Award
Quay Steven C
President & CEO
CEO / President 950 000
Value: $572.9K
Oct 14, 2025
Buy
Stock Option (right to buy)
A-Award
Daniel Mark James
Chief Financial Officer
C-Suite Officer 578 000
Value: $595.3K
Oct 14, 2025
Buy
Common Stock
J-Other
Daniel Mark James
Insider
Other 0
Value: $0
May 21, 2025
Buy
Common Stock
P-Purchase
Quay Steven C
President & CEO
CEO / President 11 239
Value: $10K
May 21, 2025
Buy
Common Stock
P-Purchase
Quay Steven C
President & CEO
CEO / President 11 239
Value: $10K
May 15, 2025
Buy
Stock Option (right to buy)
A-Award
Finn Jonathan
Director
Director 125 000
Value: $123.8K
May 15, 2025
Buy
Stock Option (right to buy)
A-Award
Chen Shu-chih
Director
Director 125 000
Value: $123.8K
May 15, 2025
Buy
Stock Option (right to buy)
A-Award
Quay Steven C
President & CEO
CEO / President 1 366 062
Value: $1.35M
May 15, 2025
Buy
Stock Option (right to buy)
A-Award
Rees Heather
Chief Financial Officer
C-Suite Officer 543 785
Value: $538.3K
May 15, 2025
Buy
Stock Option (right to buy)
A-Award
Galli Stephen J
Director
Director 125 000
Value: $123.8K
May 15, 2025
Buy
Stock Option (right to buy)
A-Award
Remmel H. Lawrence
Director
Director 125 000
Value: $123.8K
May 15, 2025
Buy
Stock Option (right to buy)
A-Award
Cigler Tessa
Director
Director 125 000
Value: $123.8K
May 15, 2025
Buy
Stock Option (right to buy)
A-Award
Steinhart Richard I
Director
Director 125 000
Value: $123.8K
May 15, 2025
Buy
Stock Option (right to buy)
A-Award
Steinhart Richard I
Director
Director 125 000
Value: $123.8K
May 15, 2025
Buy
Stock Option (right to buy)
A-Award
Cigler Tessa
Director
Director 125 000
Value: $123.8K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

Click to get the best stock tips daily for free!
ABOUT ATOSSA GENETICS INC.
Atossa Genetics
Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of medicines in the areas of oncology and infectious diseases. The company's lead program is Endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It is also developing AT-H201, an inhalation therapy to improve lung function in severely ill and hospitalized COVID-19 patien...
GOLDEN STAR
Ticker Change Signal Date
IDYA
$28.98
18.12% Jun 12
DHI
$146.71
6.29% Jun 10
PHM
$118.49
6.02% Jun 10
EAT
$140.46
17.09% Jun 05
E
ETD
$20.67
3.19% Jun 05

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE